Protagonist Therapeutics patents new SLC40A1 ligands
Oct. 26, 2022
Protagonist Therapeutics Inc. has disclosed hepcidin mimetic conjugates acting as solute carrier family 40 member 1 (SLC40A1, ferroportin) ligands with extended half-life and stability.